

**Literaturverzeichnis zum Titelthema „Neu in der Schmerztherapie“
von Doris M. Wagner, DESA
Bayerisches Ärzteblatt 11/2022, Seite 544 ff.**

1. Kawai K et al.: Systematic review of incidence and complications of Herpes zoster: towards a global perspective. *BMJ open* 2014;4(6):e004833;
2. Johnson BH et al.: Annual incidence rates of Herpes zoster among an immunocompetent population in the United States. *BMC Infect Dis* 2015;15:502
3. Ultsch B et al.: Herpes zoster in Germany: Quantifying the burden of disease. *BMC Infect Dis* 2011;11:173
4. Nagel MA et al.: Varicella zoster virus vasculopathy: the expanding clinical spectrum and pathogenesis. *J Neuroimmunol* 2017;308:112-7
5. Gelbe Liste Pharmaindex. https://www.gelbe-liste.de/wirkstoffe/Capsaicin_15268#Wirkmechanismus
6. Derry S et al.: Topical Capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev* 2017;1(1):CD0007393
7. AWMF-S2k-Leitlinie „Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen“. https://www.awmf.org/uploads/tx_szleitlinien/030-114I_S2k_Diagnose-nicht-interventionelle-Therapie-neuropathischer-Schmerzen_2022-06.pdf (abgerufen am 13.10.2022)
8. Qutenza® 179 mg kutanes Pflaster (Capsaicin) – Leitfaden zur Verringerung von Arzneimittel- und Anwendungsrisiken – Angehörige der Heilberufe.
9. Lipton RB et al.: Migraine: epidemiology, impact, and risk factors for progression. *Headache*. 2005 Apr;45 Suppl 1:S3-S13. doi: 10.1111/j1526-4610.20054501001.x. PMID: 15833088.
10. Diener HC. et al.: Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2018, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien (abgerufen am 18.10.2022)
11. Blumenfeld AM et al.: Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). *Cephalalgia* 2011;31:301-315
12. Straube A. et al.: Therapie und Versorgung der chronischen Migräne. *Nervenarzt* 2012;83(12):1600-08
13. Anttila V et al.: Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. *Nature Genetics*. doi:10.1038/ng.652.
14. Anttila V et al.: Genome-wide meta-analysis identifies new susceptibility loci for migraine. *Nature Genetics*. doi:10.1038/ng.2676.
15. Rosenfeld MG et al.: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. *Nature*. 1983;304:129-135
16. Edvinsson L et al.: CGRP as the target of new migraine therapies – successful translation from bench to clinic. *Nat Rev Neurol* 2018;14:338-50
17. Lassen LH et al.: CGRP may play a causative role in migraine. *Cephalalgia* 2002;22:54-61
18. Ashina M et al.: Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). *Cephalalgia*. 2020;40(3):241-254. doi:10.1177/0333102420905132.
19. Dodick DW et al.: ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. *Cephalalgia*. 2018;38(6):1026-1037. doi:10.1177/0333102418759786.
20. Goadsby PJ et al.: A controlled trial of erenumab for episodic migraine. *N Engl J Med*. 2017 Nov 30;377(22):2123-2132. doi:10.1056/NEJMoa1705848.

21. Dodick DW et al.: Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. *JAMA*. 2018;319(19):1999-2008. doi:10.1001/jama.2018.4853
22. Stauffer VL et al.: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. *JAMA Neurol*. 2018;75(9):1080-1088. doi:10.1001/jamaneurol.2018.1212.
23. Skljarevski V et al.: Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. *Cephalalgia*. 2018;38(8):1442-1454. doi:10.1177/0333102418779543.
24. Lipton RB et al.: Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. *Neurology*. 2020;94(13):e1365-31377. doi:10.1212/WNL.0000000000009169.
25. Tepper S et al.: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol*. 2017;16(6):425-434. doi:10.1016/S1474-4422(17)30083-2.
26. Silberstein SD et al.: Fremanezumab for the preventive treatment of chronic migraine. *N Engl J Med*. 2017;377(22):2113-2122. doi:10.1056/NEJMoa1709038.
27. Detke HC et al.: Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. *Neurology*. 2018;91(24):e2211-e2221. doi:10.1212/WNL0000000000006640.
28. Harden RN et al.: Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. *Pain*. 2010;150:268-274
29. Sandroni P et al.: Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. *Pain*. 2003;103:199-207.
30. De Mos M et al.: The incidence of complex regional pain syndrome: a population-based study. *Pain*. 2007;129:12-20.
31. Stanton-Hicks M.: Plasticity of complex regional pain syndrome (CROS) in children *Pain Med*. 2010;11:1216-23.
32. Bean DJ et al.: Extent of recovery in the first 12 months of complex regional pain syndrome type-1: a prospective study. *Eur J Pain*. 2016;20:884-894.
33. Birklein F et al.: Activation of cutaneous immune responses in complex regional pain syndrome. *J Pain*. 2014;15:485-495.
34. He L et al.: Methylprednisolone prevents nerve injury-induced hyperalgesia in neprilysin knockout mice. *Pain*. 2014;155:574-580.
35. Moseley GL et al.: Spatially defined modulation of skin temperature and hand ownership of both hands in patients with unilateral complex regional pain syndrome. *Brain*. 2012;135:3676-3686.
36. Melzack R et al.: Pain mechanisms: a new theory. *Science*. 1965;150:971-979
37. DGS-Praxisleitlinie Epidurale Rückenmarkstimulation zur Therapie chronischer Schmerzen: www.dgs-praxisleitlinien.de/index.php/leitlinien/epidurale_rueckenmarksstimulation_zur_therapie_chronischer_schmerzen